Symbols / JBIO Stock $24.98 -0.91% Jade Biosciences, Inc.
JBIO (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. It develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. The company also develops JADE201 and JADE-003, which are in preclinical development stage. Jade Biosciences, Inc. has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. is based in Waltham, Massachusetts.
Ratings
Current target
$24.98
Low
$16.00
High
$40.00
Mean
$28.71
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-25 | main | HC Wainwright & Co. | Buy → Buy | $35 |
| 2026-03-16 | main | BTIG | Buy → Buy | $39 |
| 2026-03-11 | main | Guggenheim | Buy → Buy | $23 |
| 2026-03-09 | reit | Wedbush | Outperform → Outperform | $24 |
| 2026-01-07 | init | HC Wainwright & Co. | — → Buy | $25 |
| 2025-11-25 | init | Clear Street | — → Buy | $25 |
| 2025-11-18 | main | Guggenheim | Buy → Buy | $17 |
| 2025-10-09 | init | BTIG | — → Buy | $28 |
| 2025-08-14 | main | Wedbush | Outperform → Outperform | $18 |
| 2025-06-16 | up | Guggenheim | Neutral → Buy | $14 |
| 2025-05-15 | reit | Wedbush | Outperform → Outperform | $17 |
| 2025-05-07 | init | Wedbush | — → Outperform | $17 |
- New Jade medical chief gets 500,000 stock options at $25.38 - Stock Titan hu, 23 Apr 2026 11
- Jade Biosciences (NASDAQ:JBIO) Shares Up 9.7% - What's Next? - MarketBeat Wed, 22 Apr 2026 16
- Jade Biosciences, Inc. Grants Equity Award to New Chief Medical Officer Edward R. Conner, M.D. - Quiver Quantitative hu, 23 Apr 2026 11
- We're Hopeful That Jade Biosciences (NASDAQ:JBIO) Will Use Its Cash Wisely - simplywall.st ue, 21 Apr 2026 13
- Jade Biosciences: Caution Advised Before Clinical Trial Results (NASDAQ:JBIO) - Seeking Alpha Sun, 19 Apr 2026 13
- Jade Biosciences (JBIO) price target increased by 10.24% to 28.82 - MSN Fri, 24 Apr 2026 17
- Companies Like Jade Biosciences (NASDAQ:JBIO) Are In A Position To Invest In Growth - Yahoo Finance Sat, 28 Mar 2026 07
- Jade Biosciences (JBIO) Stock Hits 52-Week High (+4.43%) 2026-04-18 - Bullish Pattern - Cổng thông tin điện tử tỉnh Tây Ninh Sat, 18 Apr 2026 23
- Jade brings in new CMO ahead of kidney disease trial and Phase 1 data - Stock Titan Wed, 22 Apr 2026 11
- Jade Biosciences Elevates Andrew King to R&D President - TipRanks Wed, 22 Apr 2026 11
- H.C. Wainwright Initiates Jade Biosciences (JBIO) at Buy With $25 PT as JADE101 Eyes $926M Peak Revenue - Yahoo Finance Mon, 19 Jan 2026 08
- Andrew King becomes President of R&D at Jade Biosciences (NASDAQ: JBIO) - Stock Titan Wed, 22 Apr 2026 11
- 867,284 Shares in Jade Biosciences, Inc. $JBIO Bought by Aberdeen Group plc - MarketBeat Wed, 08 Apr 2026 07
- Jade Biosciences (NASDAQ: JBIO) — director votes, auditor and jury‑waiver amendment - Stock Titan Fri, 17 Apr 2026 20
- Can Jade Biosciences (JBIO) Stock Maintain Growth | Price at $18.30, Up 2.29% - Popular Trader Picks - Cổng thông tin điện tử tỉnh Lào Cai Mon, 13 Apr 2026 07
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2025-12-31 |
|---|---|---|
| Total Revenue |
|
0.00
|
| Operating Revenue |
|
0.00
|
| Operating Expense |
|
113.54
|
| Research And Development |
|
93.12
|
| Selling General And Administration |
|
20.42
|
| General And Administrative Expense |
|
20.42
|
| Salaries And Wages |
|
12.69
|
| Other Gand A |
|
7.73
|
| Total Expenses |
|
113.54
|
| Operating Income |
|
-113.54
|
| Total Operating Income As Reported |
|
-113.54
|
| EBITDA |
|
-113.52
|
| Normalized EBITDA |
|
-113.52
|
| Reconciled Depreciation |
|
0.03
|
| EBIT |
|
-113.54
|
| Net Income |
|
-127.41
|
| Pretax Income |
|
-127.35
|
| Net Non Operating Interest Income Expense |
|
7.78
|
| Net Interest Income |
|
7.78
|
| Interest Income Non Operating |
|
7.78
|
| Interest Income |
|
7.78
|
| Other Income Expense |
|
-21.59
|
| Other Non Operating Income Expenses |
|
-21.59
|
| Tax Provision |
|
0.06
|
| Tax Rate For Calcs |
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-127.41
|
| Net Income From Continuing Operation Net Minority Interest |
|
-127.41
|
| Net Income From Continuing And Discontinued Operation |
|
-127.41
|
| Net Income Continuous Operations |
|
-127.41
|
| Normalized Income |
|
-127.41
|
| Net Income Common Stockholders |
|
-127.41
|
| Diluted NI Availto Com Stockholders |
|
-127.41
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 |
|---|---|---|---|
| Total Assets |
|
349.78
+380.48%
|
72.80
|
| Current Assets |
|
348.82
+400.78%
|
69.65
|
| Cash Cash Equivalents And Short Term Investments |
|
336.16
+384.48%
|
69.39
|
| Cash And Cash Equivalents |
|
88.44
+27.46%
|
69.39
|
| Other Short Term Investments |
|
247.72
|
0.00
|
| Other Current Assets |
|
12.66
+4623.13%
|
0.27
|
| Total Non Current Assets |
|
0.96
-69.32%
|
3.15
|
| Net PPE |
|
0.90
|
0.00
|
| Gross PPE |
|
0.90
|
0.00
|
| Other Properties |
|
0.90
|
—
|
| Other Non Current Assets |
|
0.07
-97.81%
|
3.15
|
| Total Liabilities Net Minority Interest |
|
17.26
-85.57%
|
119.60
|
| Current Liabilities |
|
16.54
+37.87%
|
12.00
|
| Payables And Accrued Expenses |
|
13.22
+62.60%
|
8.13
|
| Payables |
|
2.15
+66.74%
|
1.29
|
| Accounts Payable |
|
2.15
+66.74%
|
1.29
|
| Current Accrued Expenses |
|
11.06
+61.82%
|
6.84
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
3.32
+19.06%
|
2.79
|
| Other Current Liabilities |
|
—
|
1.08
|
| Total Non Current Liabilities Net Minority Interest |
|
0.72
-99.33%
|
107.60
|
| Long Term Debt And Capital Lease Obligation |
|
0.72
-99.33%
|
107.60
|
| Long Term Debt |
|
—
|
107.60
|
| Long Term Capital Lease Obligation |
|
0.72
|
0.00
|
| Preferred Securities Outside Stock Equity |
|
0.00
-100.00%
|
0.00
|
| Stockholders Equity |
|
332.52
+810.52%
|
-46.80
|
| Common Stock Equity |
|
332.52
+810.52%
|
-46.80
|
| Capital Stock |
|
0.01
+600.00%
|
0.00
|
| Common Stock |
|
0.01
+400.00%
|
0.00
|
| Preferred Stock |
|
0.00
|
0.00
|
| Share Issued |
|
49.32
+52.99%
|
32.24
|
| Ordinary Shares Number |
|
49.32
+52.99%
|
32.24
|
| Additional Paid In Capital |
|
506.77
+283012.29%
|
0.18
|
| Retained Earnings |
|
-174.39
-271.21%
|
-46.98
|
| Gains Losses Not Affecting Retained Earnings |
|
0.13
|
0.00
|
| Other Equity Adjustments |
|
0.13
|
—
|
| Total Equity Gross Minority Interest |
|
332.52
+810.52%
|
-46.80
|
| Total Capitalization |
|
332.52
+446.90%
|
60.80
|
| Working Capital |
|
332.28
+476.29%
|
57.66
|
| Invested Capital |
|
332.52
+446.89%
|
60.80
|
| Total Debt |
|
0.72
-99.33%
|
107.60
|
| Net Debt |
|
—
|
38.21
|
| Capital Lease Obligations |
|
0.72
|
0.00
|
| Net Tangible Assets |
|
332.52
+810.52%
|
-46.80
|
| Tangible Book Value |
|
332.52
+810.52%
|
-46.80
|
| Preferred Stock Equity |
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 |
|---|---|---|
| Operating Cash Flow |
|
-94.69
|
| Cash Flow From Continuing Operating Activities |
|
-94.69
|
| Net Income From Continuing Operations |
|
-127.41
|
| Depreciation Amortization Depletion |
|
0.03
|
| Depreciation |
|
0.03
|
| Depreciation And Amortization |
|
0.03
|
| Other Non Cash Items |
|
21.67
|
| Stock Based Compensation |
|
20.01
|
| Change In Working Capital |
|
-8.20
|
| Change In Prepaid Assets |
|
-11.97
|
| Change In Payables And Accrued Expense |
|
3.77
|
| Change In Accrued Expense |
|
3.41
|
| Change In Payable |
|
0.36
|
| Change In Account Payable |
|
0.36
|
| Change In Other Current Assets |
|
-0.04
|
| Change In Other Current Liabilities |
|
0.04
|
| Investing Cash Flow |
|
-247.01
|
| Cash Flow From Continuing Investing Activities |
|
-247.01
|
| Net PPE Purchase And Sale |
|
-0.20
|
| Purchase Of PPE |
|
-0.20
|
| Capital Expenditure |
|
-0.20
|
| Net Investment Purchase And Sale |
|
-246.78
|
| Purchase Of Investment |
|
-261.19
|
| Sale Of Investment |
|
14.41
|
| Net Other Investing Changes |
|
-0.03
|
| Financing Cash Flow |
|
360.77
|
| Cash Flow From Continuing Financing Activities |
|
360.77
|
| Net Issuance Payments Of Debt |
|
0.00
|
| Issuance Of Debt |
|
0.00
|
| Long Term Debt Issuance |
|
0.00
|
| Net Long Term Debt Issuance |
|
0.00
|
| Net Common Stock Issuance |
|
189.11
|
| Proceeds From Stock Option Exercised |
|
0.38
|
| Net Other Financing Charges |
|
171.27
|
| Changes In Cash |
|
19.07
|
| Effect Of Exchange Rate Changes |
|
-0.02
|
| Beginning Cash Position |
|
69.39
|
| End Cash Position |
|
88.44
|
| Free Cash Flow |
|
-94.89
|
| Amortization Of Securities |
|
-0.78
|
| Common Stock Issuance |
|
189.11
|
| Issuance Of Capital Stock |
|
189.11
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-22 View
- 8-K2026-04-02 View
- 10-K2026-03-06 View
- 8-K2026-03-06 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 42026-02-13 View
- 8-K2026-01-05 View
- 8-K2025-12-15 View
- 10-Q2025-11-14 View
- 8-K2025-11-14 View
- 42025-10-08 View
- 8-K2025-10-07 View
- 8-K2025-09-09 View
- 10-Q2025-08-13 View
- 8-K2025-08-13 View
- 42025-07-14 View
- 8-K2025-07-01 View
- 42025-05-19 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|